Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Summary

This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as flotetuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2020-10-20

Primary completion

2020-10-20

Completion

2020-10-20

Drugs

Indications